Initos Pharmaceuticals LLC — Department of Health and Human Services STTR Phase I: 999

Description

DESCRIPTION provided by applicant Antisense and siRNA oligonucleotides offer the promise of highly precise manipulation of genes involved in disease pathogenesis However despite the investment of enormous resources that promise has been fulfilled to only a limited degree A key impediment to oligonucleotide based therapeutics is the difficulty in delivering these large highly polar molecules to their sites of action in the cytosol or nucleus of tissue cells While chemical modification of oligonucleotides and the utilization of various nanotechnology based delivery approaches have been helpful the delivery problem remains challenging Much of the oligonucleotide accumulated by cells remains non productively entrapped in endosomes The complex pathways of endocytosis and intracellular trafficking are being increasingly understood at the molecular level however there is a paucity of small molecule probes for these pathways Here we describe a novel technology based on the use of small organic molecules to enhance the functional delivery and pharmacological effectiveness of oligonucleotides by manipulating their intracellular trafficking We have established a proof of principle for this strategy by identifying compounds using a high throughout screen of andgt small molecules Three distinct compound series were discovered from this screen that significantly enhance oligonucleotide effects in cell culture and in one case in a transgenic mouse model We now propose medicinal chemistry efforts to build structure activity relationships and improve both potency and pharmacological properties with the end goal of creating molecules that can effectively and safely be used in vivo Promising leads will be examined for their pharmacokinetic and biodistribution behavior Finally these leads will be evaluated in a xenograft tumor model The identification of potent and non toxic enhancing molecules will likely have a major impact on the entire field of oligonucleotide therapeutics PUBLIC HEALTH RELEVANCE A key impediment to oligonucleotide based therapeutics is the difficulty in delivering these large highly polar molecules to their sites of action in the cyosol or nucleus of tissue cells While chemical modification of oligonucleotides and the utilization of various nanotechnology based delivery approaches have been helpful the delivery problem remains largely unresolved We have taken an orthogonal approach to this problem and have developed small molecule compounds that enhance the functional delivery and pharmacological effectiveness of oligonucleotides by manipulating their intracellular trafficking Here we propose to optimize compounds as in vivo probes it seems likely that this effort will have a major impact on the entire field of oligonucleotide therapeutics